

Markus Hohenfellner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10266878/publications.pdf>

Version: 2024-02-01

104
papers

3,488
citations

201385

27
h-index

149479

56
g-index

107
all docs

107
docs citations

107
times ranked

4836
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 8.e11-8.e18.	0.8	8
2	A Platform and Multisided Market for Translational, Software-Defined Medical Procedures in the Operating Room (OP 4.1): Proof-of-Concept Study. <i>JMIR Medical Informatics</i> , 2022, 10, e27743.	1.3	1
3	Re: Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort. <i>European Urology</i> , 2022, 81, 315-316.	0.9	0
4	cMET: a prognostic marker in papillary renal cell carcinoma?. <i>Human Pathology</i> , 2022, 121, 1-10.	1.1	3
5	Age-stratified outcomes after radical prostatectomy in a randomized setting (LAP-01): do younger patients have more to lose?. <i>World Journal of Urology</i> , 2022, 40, 1151-1158.	1.2	4
6	Impact of Surgeon's Experience in Rigid Versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores. <i>Cancers</i> , 2022, 14, 886.	1.7	3
7	The prognostic impact of Claudin 6 in papillary renal cell carcinoma. <i>Pathology Research and Practice</i> , 2022, 231, 153802.	1.0	2
8	Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort. <i>Journal of Cancer</i> , 2022, 13, 1706-1712.	1.2	5
9	Robotic-assisted Versus Laparoscopic Radical Prostatectomy: 12-month Outcomes of the Multicentre Randomised Controlled LAP-01 Trial. <i>European Urology Focus</i> , 2022, 8, 1583-1590.	1.6	14
10	Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01). <i>Prostate</i> , 2022, 82, 894-903.	1.2	2
11	Evolution of Salvage Radical Prostatectomy from Open to Robotic and Further to Retzius Sparing Surgery. <i>Journal of Clinical Medicine</i> , 2022, 11, 202.	1.0	7
12	Interleukin-2 and Interferon- γ for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period. <i>Urologia Internationalis</i> , 2022, 106, 1158-1167.	0.6	1
13	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 143-151.	3.3	25
14	Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. <i>European Urology Focus</i> , 2021, 7, 102-110.	1.6	28
15	Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 53-59.e1.	0.9	6
16	<sc>PARP</sc> inhibition in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 344-351.	1.5	2
17	Evaluation of new motorized articulating laparoscopic instruments by laparoscopic novices using a standardized laparoscopic skills curriculum. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 979-988.	1.3	5
18	Diagnostic Accuracy of ¹⁸ F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2021, 62, 208-213.	2.8	77

#	ARTICLE	IF	CITATIONS
19	The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. <i>European Urology Focus</i> , 2021, 7, 325-331.	1.6	34
20	miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells. <i>Cancers</i> , 2021, 13, 964.	1.7	5
21	Predicting the Risk of Metastases by PSMA-PET/CT Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma. <i>Cancers</i> , 2021, 13, 1508.	1.7	8
22	Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study. <i>Cancers</i> , 2021, 13, 1623.	1.7	4
23	Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery. <i>Biomedicines</i> , 2021, 9, 627.	1.4	5
24	Re: Adjuvant Radiotherapy Versus Early Salvage Radiotherapy Following Radical Prostatectomy (TROG) Tj ETQq0 0 0 rgBT /Overlock 10 T 79, 893-894.	0.9	1
25	Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01). <i>European Urology</i> , 2021, 79, 750-759.	0.9	54
26	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. <i>Scientific Reports</i> , 2021, 11, 14244.	1.6	9
27	Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease – A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy. <i>European Urology Focus</i> , 2020, 6, 1205-1212.	1.6	39
28	Recovery of pad-free continence in elderly men does not differ from younger men undergoing robot-assisted radical prostatectomy for aggressive prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 351-360.	1.2	7
29	Patients Resistant Against PSMA-Targeting α -Radiation Therapy Often Harbor Mutations in DNA Damage-Repair Associated Genes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 683-688.	2.8	61
30	Response Prediction of ^{177}Lu -PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. <i>Journal of Nuclear Medicine</i> , 2020, 61, 689-695.	2.8	39
31	Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2020, 13, 336-345.	1.7	52
32	Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 736.e1-736.e10.	0.8	2
33	Detection of AR-V7 in primary prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 28, 100230.	0.7	0
34	Microenvironment-Derived FGF-2 Stimulates Renal Cell Carcinoma Cell Proliferation through Modulation of p27 ^{Kip1} : Implications for Spatial Niche Formation and Functional Intratumoral Heterogeneity. <i>Pathobiology</i> , 2020, 87, 114-124.	1.9	11
35	Antibody selection influences the detection of AR-V7 in primary prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100186.	0.7	10
36	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer – Results from a prospective pilot study using a 37 gene panel. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 637.e17-637.e27.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Laminâ€B1 is a senescenceâ€associated biomarker in clearâ€cell renal cell carcinoma. <i>Oncology Letters</i> , 2019, 18, 2654-2660.	0.8	24
38	Retzius-sparing robot-assisted laparoscopic radical prostatectomy: functional and early oncologic results in aggressive and locally advanced prostate cancer. <i>BMC Urology</i> , 2019, 19, 113.	0.6	34
39	Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. <i>PLoS ONE</i> , 2019, 14, e0221350.	1.1	13
40	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1983-1992.	0.5	18
41	Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. <i>Oncotarget</i> , 2019, 10, 17-29.	0.8	21
42	Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancerâ€29-Year Follow-up. <i>European Urology</i> , 2019, 75, 1036.	0.9	0
43	High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. <i>Human Pathology</i> , 2019, 83, 212-223.	1.1	23
44	Dosimetry Estimate and Initial Clinical Experience with ⁹⁰ Y-PSMA-617. <i>Journal of Nuclear Medicine</i> , 2019, 60, 806-811.	2.8	27
45	Biochemical Recurrence of Prostate Cancer: Initial Results with [¹⁸ F]PSMA-1007 PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 632-635.	2.8	55
46	Targeted Î±-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵ Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. <i>Journal of Nuclear Medicine</i> , 2018, 59, 795-802.	2.8	322
47	Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL. <i>Future Science OA</i> , 2018, 4, FSO299.	0.9	3
48	Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit. <i>European Urology Focus</i> , 2018, 4, 540-546.	1.6	18
49	Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancer. <i>Current Opinion in Urology</i> , 2018, 28, 172-177.	0.9	13
50	Simultaneous whole-body ¹⁸ Fâ€PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 340-347.	3.3	32
51	Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsyâ€naïve patients. <i>BJU International</i> , 2018, 121, 53-60.	1.3	47
52	Complete bladder neck preservation promotes long-term post-prostatectomy continence without compromising midterm oncological outcome: analysis of a randomised controlled cohort. <i>World Journal of Urology</i> , 2018, 36, 349-355.	1.2	23
53	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e11-79.e17.	0.8	14
54	Repeated ¹⁷⁷ Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. <i>Journal of Nuclear Medicine</i> , 2018, 59, 459-465.	2.8	68

#	ARTICLE	IF	CITATIONS
55	Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. <i>Scientific Reports</i> , 2018, 8, 16708.	1.6	27
56	Multiparametric MRI and MRI/TRUS Fusion Guided Biopsy for the Diagnosis of Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 87-98.	0.8	3
57	Prostatic metastasis from intrahepatic cholangiocarcinoma. <i>Urology Case Reports</i> , 2018, 20, 90-91.	0.1	4
58	Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. <i>Oncotarget</i> , 2018, 9, 22537-22545.	0.8	4
59	Ureterocystoneostomy in complex oncological cases with an "Uebelhoer"-modified Boari bladder flap. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 1271-1278.	0.8	6
60	Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. <i>World Journal of Urology</i> , 2017, 35, 245-250.	1.2	8
61	Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer—Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. <i>European Urology</i> , 2017, 72, 888-896.	0.9	136
62	Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1258-1268.	3.3	425
63	Intraindividual Comparison of ¹⁸ F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1805-1810.	2.8	91
64	The Value of PSA Density in Combination with PI-RADS _{v2} for the Accuracy of Prostate Cancer Prediction. <i>Journal of Urology</i> , 2017, 198, 575-582.	0.2	179
65	Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 637-644.	0.8	22
66	Three-Dimensional Reconstruction of Preoperative Imaging Improves Surgical Success in Laparoscopy. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2017, 27, 181-185.	0.5	12
67	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 776-787.	3.3	124
68	Expression and Functional Characterization of the BNIP3 Protein in Renal Cell Carcinomas. <i>Translational Oncology</i> , 2017, 10, 869-875.	1.7	15
69	Results of a Patient Survey for Assessment Services in Renal Transplant Patients With a History of Cancer. <i>Progress in Transplantation</i> , 2017, 27, 365-368.	0.4	0
70	Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. <i>BJU International</i> , 2017, 120, 631-638.	1.3	104
71	Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers. <i>Journal of Cancer</i> , 2017, 8, 507-512.	1.2	2
72	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. <i>Oncotarget</i> , 2017, 8, 74049-74057.	0.8	14

#	ARTICLE	IF	CITATIONS
73	MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. <i>Oncotarget</i> , 2017, 8, 1046-1057.	0.8	26
74	Prognostic relevance of androgen receptor expression in renal cell carcinomas. <i>Oncotarget</i> , 2017, 8, 78545-78555.	0.8	15
75	Evaluation of an Automated Analysis Tool for Prostate Cancer Prediction Using Multiparametric Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2016, 11, e0159803.	1.1	14
76	The complex interplay of physician, patient, and spouse in preoperative counseling for radical prostatectomy: a comparative mixed-method analysis of 30 videotaped consultations. <i>Psycho-Oncology</i> , 2016, 25, 949-956.	1.0	7
77	Paraganglioma of the Seminal Vesicle Case Report and Review of the Literature. <i>Journal of Endourology Case Reports</i> , 2016, 2, 227-231.	0.3	5
78	Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 238.e9-238.e17.	0.8	7
79	Risk factors for long-term outcome in photoselective vaporization of the prostate. <i>Scandinavian Journal of Urology</i> , 2016, 50, 313-318.	0.6	1
80	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. <i>Journal of Surgical Oncology</i> , 2016, 114, 764-768.	0.8	26
81	Intraoperative Computed Tomography Imaging for Navigated Laparoscopic Renal Surgery: First Clinical Experience. <i>Journal of Endourology</i> , 2016, 30, 1105-1111.	1.1	30
82	Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 221-228.	1.4	26
83	Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 433.e1-433.e8.	0.8	21
84	Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. <i>European Urology</i> , 2016, 70, 846-853.	0.9	258
85	Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e379-e385.	0.9	13
86	Adjuvant therapy for renal-cell carcinoma: settled for now. <i>Lancet, The</i> , 2016, 387, 1973-1974.	6.3	17
87	Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. <i>Oncotarget</i> , 2016, 7, 59589-59603.	0.8	38
88	The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker. <i>Oncotarget</i> , 2016, 7, 418-432.	0.8	28
89	Clinical factors predictive for efficacy of treatment with cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) in second and later lines. <i>Journal of Clinical Oncology</i> , 2016, 34, e16511-e16511.	0.8	0
90	PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas. <i>Journal of Pathology</i> , 2015, 237, 460-471.	2.1	18

#	ARTICLE	IF	CITATIONS
91	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. <i>Journal of Urology</i> , 2015, 193, 436-442.	0.2	27
92	The Impact of Magnetic Resonance Imaging on Prediction of Extraprostatic Extension and Prostatectomy Outcome in Patients with Low-, Intermediate- and High-Risk Prostate Cancer: Try to Find a Standard. <i>Journal of Endourology</i> , 2015, 29, 1396-1405.	1.1	32
93	Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e145-e152.	0.9	16
94	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. <i>Journal of Urology</i> , 2015, 194, 304-309.	0.2	28
95	Primary melanoma of the prostate: case report and review of the literature. <i>BMC Urology</i> , 2015, 15, 68.	0.6	14
96	Interdisciplinary counseling service for renal malignancies: A patient-centered approach to raise guideline adherence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 23.e1-23.e7.	0.8	11
97	Comparative Analysis of Transperineal Template Saturation Prostate Biopsy Versus Magnetic Resonance Imaging Targeted Biopsy with Magnetic Resonance Imaging-Ultrasound Fusion Guidance. <i>Journal of Urology</i> , 2015, 193, 87-94.	0.2	196
98	The current and future role of magnetic resonance imaging in prostate cancer detection and management. <i>Translational Andrology and Urology</i> , 2015, 4, 326-41.	0.6	29
99	Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013". <i>Radiation Oncology</i> , 2014, 9, 224.	1.2	1
100	Preoperative decision making for renal cell carcinoma: Cystic morphology in cross-sectional imaging might predict lower malignant potential. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 37.e1-37.e6.	0.8	21
101	Management of Male Urethral Emergencies. <i>Urology Practice</i> , 2014, 1, 92-99.	0.2	0
102	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. <i>European Urology</i> , 2014, 66, 577-583.	0.9	76
103	Critical evaluation of MRI-targeted TRUS-guided transperineal fusion biopsy for detection of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e16063-e16063.	0.8	0
104	Positive surgical margins after partial nephrectomy. <i>Nature Reviews Urology</i> , 2010, 7, 240-242.	1.9	0